ArticleScientific reports2025
Low GATA3 predicts worse survival in penile cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From biology to morphology and treatment: the current role of pathology in penile cancer - a narrative review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Penile squamous cell carcinoma (pSCC) is a rare genitourinary tumor associated with notable psychosexual distress and poor prognosis. Traditional prognostic factors for pSCC include TNM stage and histological grade, with lymph node metastases being a critical indicator of poor prognosis. This study aimed to evaluate the prognostic impact of the following immunohistochemistry markers routinely used in histopathology practice: GATA3, IMP3, HIF-1-α, CK7, CA-IX, HER2, and TTF-1. A retrospective cohort of 145 patients with pSCC was analyzed using tissue microarray and immunohistochemical techniques. Overall survival (OS) was correlated statistically with detected marker expression. Key findings include that low GATA3 expression is associated with significantly worse OS in univariate Cox regression truncated at 3 years of follow-up. Low GATA3 retained prognostic impact when adjusted for major clinicopathological variables: Age, pT and pN stage, grade, lymphatic, venous, and perineural invasion, lymphocytic infiltrate, and expression of p16, p53, and PD-L1. Low GATA3 expression was associated with shorter cancer-specific survival (CSS) at 10 years follow-up. IMP3, CK7, and CA-IX showed statistically insignificant trends towards poorer prognosis. CK7 and CA-IX were more frequently expressed in high grade pSCC and in p16/HPV-positive tumors. IMP3 and CA-IX were associated with regional lymph node metastases. All cases were negative in TTF-1 and HER2. This study suggests GATA3 as a potential prognostic marker in pSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.